• MK-5108 (VX-689): From Target to Tumor Model

  2026-09-08

  Explore how MK-5108 (VX-689), a highly selective Aurora A inhibitor, can connect target validation with cancer cell line proliferation assays and xenograft studies. This article emphasizes assay design, evidence interpretation, and translational limitations rather than repeating standard product or disease summaries.

• Caspase-3 Fluorometric Assay Kit Workflow

  2026-09-07

  Turn apoptosis experiments into quantitative caspase activity measurements with a fast DEVD-AFC fluorescence workflow. This guide shows how to connect treatment design, autophagy–apoptosis biology, controls, and troubleshooting for more interpretable results.

• ABT-888 (Veliparib) in Translational DDR Research

  2026-09-07

  ABT-888 (Veliparib) offers translational researchers a selective PARP1/2 perturbation tool for testing DNA repair inhibition, chemotherapy and radiation sensitization, and genotype-dependent response. This thought-leadership analysis connects preclinical colorectal cancer evidence with a recent acute leukemia study showing why DNA damage-response combinations must be evaluated in the correct biological context.

• c-Myc Tag Peptide: From Assay Control to Translation

  2026-09-05

  A mechanistic and strategic guide to using the c-Myc tag Peptide for epitope-specific assay control, fusion-protein displacement, and more disciplined translational studies of transcription factor regulation.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-09-04

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in animal and tubular epithelial cell models, the researchers connected SMYD2 inhibition with improved renal injury, reduced fibrogenic and inflammatory signaling, and modulation of Smad3, STAT3, and Smad7.

• HDAC6-Driven α-Tubulin Lactylation and Dynamics

  2026-09-04

  The reference study identifies α-tubulin lactylation at Lys40 as a metabolism-sensitive modification that promotes microtubule dynamics in neuronal cells. It further establishes HDAC6 as a catalytic writer of this modification, linking intracellular lactate to cytoskeletal remodeling, neurite outgrowth, and branching.

• β-Amanitin: From Transcription Tool to Toxin Sensor

  2026-09-03

  β-Amanitin is both a selective RNA polymerase II inhibitor and a useful reference analyte for understanding amatoxin detection. This article connects transcription biology, assay design, and the latest dual-target mushroom-toxin sensing evidence.

• H 89 2HCl for cAMP/PKA Signaling Assays

  2026-09-03

  Use H 89 2HCl to separate downstream PKA activity from upstream cAMP production in phosphorylation, neurite-growth, and neuroinflammation assays. This guide translates recent trigeminal pain findings into practical controls, dosing strategies, and troubleshooting steps while emphasizing H 89’s concentration-dependent kinase selectivity.

• Neurotensin: NTR1 Signaling and GPCR Trafficking

  2026-09-02

  Neurotensin is a 13-amino acid neuropeptide and a useful Neurotensin receptor 1 activator for studying G protein-coupled receptor signaling. The B5226 reagent combines vendor-reported high purity with defined molecular, solubility, and storage specifications for GPCR trafficking mechanism study and miRNA regulation in gastrointestinal cells.

• Reserpine (N1867): Practical Research Workflow

  2026-09-02

  Reserpine (SKU N1867) provides a characterized research reagent for controlled neurotransmitter depletion, antihypertensive mechanism, and neuropharmacology workflows where solvent compatibility and solution freshness affect reproducibility. It is intended for research use only and should not be used for diagnostic, therapeutic, medical, or veterinary applications.

• MOG (35-55) EAE Research Workflow

  2026-09-01

  Build reproducible autoimmune encephalomyelitis research around a defined myelin antigen, from peptide handling and EAE induction to neuroinflammation assay design. This workflow also shows how MOG-driven disease phenotypes can be paired with PARP7–STAT1/STAT2 measurements for mechanism-focused multiple sclerosis research.

• Berberine Hydrochloride in AKI Assay Design

  2026-09-01

  Berberine hydrochloride offers a mechanistically rich tool for metabolic, cancer, and inflammation research. This article develops a distinct assay strategy connecting its AMPK-centered biology with oxidized self-DNA and NLRP3-driven acute kidney injury while clearly separating established evidence from testable hypotheses.

• Gramine–CUL3–MTDH Axis in TNBC Ferroptosis

  2026-08-31

  The reference study identifies Gramine as a selective suppressor of triple-negative breast cancer through a CUL3–MTDH regulatory axis that activates ferroptosis. By combining target-engagement assays, genetic perturbation, ferroptosis-rescue experiments, and xenograft models, the authors connect CUL3 modulation with changes in MTDH, SLC3A2, GPX4, redox balance, and tumor growth.

• AO/PI Double Staining Kit: Practical Guide

  2026-08-31

  The AO/PI Double Staining Kit provides a rapid fluorescent cell staining workflow for separating viable, apoptotic, and necrotic cell populations by color. It is appropriate for comparative cell viability, apoptosis detection, and necrosis detection, but it should not be treated as a standalone method for confirming a specific apoptotic pathway or replacing orthogonal validation.

• AG-221 (Enasidenib) Workflow for IDH2 AML

  2026-08-30

  Build a mechanism-led AML workflow around AG-221 (Enasidenib) by pairing 2-HG measurements with viability and differentiation assays. The approach extends IDH2 inhibition into CD44-linked metabolic rewiring studies, helping distinguish on-target responses from nonspecific cytotoxicity.

8482 records 1/566 page Next 12345 下5页 Last page